UNSPSC 51342102: Enviroxime

This classification denotes an antiviral agent with the molecular formula C17H18N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 133013L556, chemically known as 1h-benzimidazol-2-amine, 6-((hydroxyimino)phenylmethyl)-1-((1-methylethyl)sulfonyl)-, (e)- but generally known as enviroxime, which bears US NIH Compound Identifier 5748733. European Medicines Agency schedules Enviroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06556MIG.

UNSPSC 51342102 Enviroxime, a Commodity code, does not reflect the actual work being solicited under this code in recent state and local opportunities. The most-recent opportunities block shows procurement of antibiotics (Doxycycline Hyclate, Ciprofloxacin Hydrochloride) and naloxone-based emergency response supplies, neither of which align with the Enviroxime classification. State and local governments appear to be using this code tag for pharmaceutical supply contracts—specifically emergency preparedness and public health medications sourced through warehouse and distribution agreements—but the code itself does not capture the scope of what is actually being bought.

The issuing bodies include state health departments and county public health authorities. Recent activity shows the Illinois Department of Public Health procuring antibiotics through the MMCAP Infuse cooperative purchasing consortium, and Seminole County, Florida soliciting naloxone and drug deactivation systems for community health initiatives. Both opportunities used competitive bidding processes (IFB and piggyback awards). Illinois and Florida are the only states with recent documented activity under this code. The code shows sparse recent procurement volume; only two opportunities appear in the recent record, and the Illinois opportunity was an already-completed award rather than an open solicitation. The Seminole County IFB, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. Activity under this code does not support reliable business development signals at this time.